1. Home
  2. AIM vs HUBC Comparison

AIM vs HUBC Comparison

Compare AIM & HUBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AIM
  • HUBC
  • Stock Information
  • Founded
  • AIM 1966
  • HUBC 2017
  • Country
  • AIM United States
  • HUBC Israel
  • Employees
  • AIM N/A
  • HUBC N/A
  • Industry
  • AIM Biotechnology: Biological Products (No Diagnostic Substances)
  • HUBC
  • Sector
  • AIM Health Care
  • HUBC
  • Exchange
  • AIM Nasdaq
  • HUBC Nasdaq
  • Market Cap
  • AIM 15.9M
  • HUBC 15.2M
  • IPO Year
  • AIM N/A
  • HUBC N/A
  • Fundamental
  • Price
  • AIM $0.20
  • HUBC $0.52
  • Analyst Decision
  • AIM Strong Buy
  • HUBC
  • Analyst Count
  • AIM 2
  • HUBC 0
  • Target Price
  • AIM $2.75
  • HUBC N/A
  • AVG Volume (30 Days)
  • AIM 403.8K
  • HUBC 819.6K
  • Earning Date
  • AIM 11-15-2024
  • HUBC 12-13-2024
  • Dividend Yield
  • AIM N/A
  • HUBC N/A
  • EPS Growth
  • AIM N/A
  • HUBC N/A
  • EPS
  • AIM N/A
  • HUBC N/A
  • Revenue
  • AIM $190,000.00
  • HUBC $33,357,000.00
  • Revenue This Year
  • AIM N/A
  • HUBC N/A
  • Revenue Next Year
  • AIM $1,086.80
  • HUBC N/A
  • P/E Ratio
  • AIM N/A
  • HUBC N/A
  • Revenue Growth
  • AIM N/A
  • HUBC N/A
  • 52 Week Low
  • AIM $0.16
  • HUBC $0.38
  • 52 Week High
  • AIM $0.62
  • HUBC $2.48
  • Technical
  • Relative Strength Index (RSI)
  • AIM 40.44
  • HUBC 35.73
  • Support Level
  • AIM $0.20
  • HUBC $0.38
  • Resistance Level
  • AIM $0.23
  • HUBC $0.45
  • Average True Range (ATR)
  • AIM 0.02
  • HUBC 0.05
  • MACD
  • AIM 0.00
  • HUBC -0.01
  • Stochastic Oscillator
  • AIM 10.75
  • HUBC 14.14

About AIM AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

About HUBC Hub Cyber Security Ltd.

Hub Cyber Security Ltd is engaged in the development of cyber products, software, quality systems, reliability, and risk management. It operates in several countries and provides cybersecurity computing appliances as well as a wide range of cybersecurity professional services. The company has two operating segments: the Product and Technology Segment, and the Professional Services Segment. The majority of its revenue comes from the professional services segment, which provides data and cybersecurity, system security and reliability solutions, as well as related services such as consulting, planning, training, integration, and ongoing servicing of cybersecurity, risk management, system quality, reliability, and security projects, including fully managed corporate cybersecurity services.

Share on Social Networks: